Publication

Article

Advertorial

Pharmacy Practice in Focus: Oncology

April 2024
Volume6
Issue 3

OPC Summer 2024: Connecting Oncology Pharmacists With Cutting-Edge Insights and Opportunities to Collaborate

This year’s event from June 20 to 21, 2024, in Austin, Texas, will offer 4.25 BCOP CE hours.

People attending a conference -- Image credit: kasto | stock.adobe.com

Image credit: kasto | stock.adobe.com

Oncology Pharmacists Connect (OPC) will be held in Austin, Texas, from June 20 to 21, 2024. Presented in partnership with Hematology/Oncology Pharmacy Association, the event gathers data reported at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, with board-certified oncology pharmacy (BCOP) continuing education (CE) sessions held on June 21 from 12 pm to 5 pm.

Pharmacy Times® sat down with OPC Cochair Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, associate editor, Pharmacy Practice in Focus: Oncology; clinical pharmacy manager, Hematology/ BMT/Cellular Therapeutics; and PGY2 oncology residency program director, University of Kansas Health System in Kansas City, Missouri, to learn more about the event and what it will provide attendees. Additionally, Mahmoudjafari addressed the value of meeting with a larger community of pharmacists working together to develop solutions for responding clinically and operationally to evidence reported at the 2024 ASCO Annual Meeting.

Pharmacy Times: What is unique about what OPC offers?

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA: I appreciate the small conference feel of OPC. I also really value the presentation style with panels as opposed to a single speaker. It enriches the entire experience, and you can learn from multiple key stakeholders.

Pharmacy Times: What is your involvement with OPC this year?

Mahmoudjafari: This year, I have the privilege of serving as cochair of the conference. I am looking forward to learning from and meeting with those in attendance.

Pharmacy Times: With significant upcoming FDA approvals and impactful updated data likely to be presented at the 2024 ASCO Annual Meeting, what is the value of OPC as an opportunity to discuss these data and breaking news with colleagues?

Mahmoudjafari: The field is rapidly evolving, so meeting with others who are also acutely aware of these shifts and are actively working to stay abreast of these updates can be a helpful way to get up to speed.

Pharmacy Times: What will OPC be offering in terms of CE and BCOP credits?

Mahmoudjafari: OPC is not only going to be offering CE for each of the sessions, but it will also be offering 4.25 BCOP CE hours this year from practice management, annual conference, and BCOP updates. Topics discussed will include precision medicine, head and neck cancer updates, prevention and updates of venous thromboembolism, and updates in acute leukemia.

Click here to review the agenda and learn more about the event.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com